[Transplantation of the bone marrow from a HLA-compatible unrelated donor after immunoablative conditioning in children with acquired aplastic anemia unresponsive to combined immunosuppressive therapy: preliminary results]

Ter Arkh. 2010;82(7):41-7.
[Article in Russian]

Abstract

Aim: To analyze the efficiency of transplantation of the bone marrow from a HLA-compatible unrelated donor and continued immunosuppressive therapy (IST) in children with aplastic anemia (AA) unresponsive to 2 courses of IST.

Subjects and methods: The study enrolled 14 children aged 2-16 years (median 9 years). A control group comprised 26 patients in whom IST was continued. The median interval between the diagnosis of AA and transplantation was 26 months (9-156 months). The conditioning regimen consisted of thoracoabdominal irradiation in a dose of 2 Gy, fludarabin (Flu) 100-150 mg/m2, cyclophosphamide (Cy) 100-200 mg/kg, antithymocyte globulin (ATG) in 11 patients and Flu, Cy, and ATG in 3. A graft-versus-host reaction was prevented with mycophenolate mefetil in all the patients, tacrolimus in 11, and cyclosporin A in 3. Donors were compatible for high-resolution typing of 10/10 and 9/10 alleles in 8 and 6 patients, respectively; the source of a transplant was bone marrow in 13 patients and granulocyte colony-stimulating factor-mobilized peripheral blood precursors in one case.

Results: Thirteen patients achieved primary engraftment after single transplantation; one patient did after repeat transplantation. Grades I to II graft-versus-host reaction (GVHR) developed in 9 patients; postengraftment life-threatening infections in 3, extensive chronic GVHR in 2, circumscribed GVHR in 7. All fourteen hemopoietic cell transplant recipients followed for a median 17.5 months (range 1-71 months) were survivors.

Conclusion: The likelihood of good survival after unrelated transplantations in AA is much higher than that after continued IST: 100% versus 15 +/- 11%.

Publication types

  • Clinical Trial
  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anemia, Aplastic / drug therapy
  • Anemia, Aplastic / etiology
  • Anemia, Aplastic / immunology
  • Anemia, Aplastic / radiotherapy
  • Anemia, Aplastic / surgery*
  • Antilymphocyte Serum / administration & dosage
  • Antilymphocyte Serum / therapeutic use*
  • Bone Marrow Transplantation / methods*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclosporine / administration & dosage
  • Cyclosporine / therapeutic use*
  • Disease-Free Survival
  • Graft Survival
  • Graft vs Host Reaction / immunology
  • HLA Antigens* / genetics
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Tissue Donors*
  • Transplantation Conditioning / methods*
  • Treatment Failure

Substances

  • Antilymphocyte Serum
  • HLA Antigens
  • Immunosuppressive Agents
  • Cyclosporine